{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:15:25Z","timestamp":1789704925071,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejim.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T12:33:36Z","timestamp":1697718816000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The current best drug treatment for hypertensive heart failure with preserved ejection fraction"],"prefix":"10.1016","volume":"120","author":[{"given":"Aurora","family":"Rist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Sevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Wachtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Devereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard P.","family":"Aurigemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto A.","family":"Smiseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-0272","authenticated-orcid":false,"given":"Sverre E.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevo","family":"Julius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.10.008_bib0001","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics - 2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.008_bib0002","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0003","doi-asserted-by":"crossref","first-page":"I223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2023.10.008_bib0004","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0006","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0007","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ejhf.2576","article-title":"Left ventricular ejection fraction as the primary heart failure phenotyping parameter","volume":"24","author":"Lund","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.10.008_bib0009","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.10.008_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12574-017-0364-2","article-title":"Evaluation of left ventricular diastolic function: state of the art after 35 years with Doppler assessment","volume":"16","author":"Smiseth","year":"2018","journal-title":"J Echocardiogr"},{"key":"10.1016\/j.ejim.2023.10.008_bib0011","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.10.008_bib0012","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.10.008_bib0013","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0014","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0016","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0017","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0018","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0019","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0020","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.008_bib0021","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0022","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.10.008_bib0023","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0025","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00392-020-01632-x","article-title":"Covariate adjusted reanalysis of the I-preserve trial","volume":"109","author":"Ferreira","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2023.10.008_bib0026","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure","volume":"6","author":"von Lueder","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0027","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.10.008_bib0028","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0029","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.10.008_bib0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF Randomized Clinical Trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2023.10.008_bib0031","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/ehjacc\/zuac144","article-title":"Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial","volume":"11","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ejim.2023.10.008_bib0032","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension\u2013cardiovascular events","volume":"387","author":"Ishani","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0033","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0034","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/hrt.2010.207365","article-title":"\u03b2-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure","volume":"97","author":"Ambrosio","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2023.10.008_bib0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2023.10.008_bib0036","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0037","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/cvr\/cvab222","article-title":"Central and peripheral sympathetic activation in heart failure","volume":"118","author":"Grassi","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2023.10.008_bib0038","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/01.hjh.0000239288.10013.04","article-title":"N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy","volume":"24","author":"Olsen","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.10.008_bib0039","unstructured":"FDA panel puts spironolactone in play for HF with preserved EF [Internet]. Medscape. [Cited 2023 July 21] Available from: https:\/\/www.medscape.com\/viewarticle\/942799."},{"key":"10.1016\/j.ejim.2023.10.008_bib0040","unstructured":"Pieske B. Spironolactone in the treatment of heart failure- a double-blind, randomized, placebo-controlled, parallel group interventional phase iii study to determine efficacy and safety of spironolactone on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid-range or preserved ejection fraction [Internet]. Clinicaltrials.gov; 2021 [cited 2023 July 21]. Report No.: NCT04727073. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04727073."},{"key":"10.1016\/j.ejim.2023.10.008_bib0041","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0042","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0043","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0044","unstructured":"FINEARTS - HF (Finerenone in heart failure patients) [Internet]. Health Research Authority. [Cited 2023 July 21]. Available from: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/finearts-hf-finerenone-in-heart-failure-patients\/."},{"key":"10.1016\/j.ejim.2023.10.008_bib0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0046","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0047","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.10.008_bib0049","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.008_bib0050","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0051","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.10.008_bib0052","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","volume":"5","author":"Martin","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2023.10.008_bib0053","article-title":"Pharmacotherapies in heart failure with preserved ejection fraction: a systematic review and network meta-analysis","author":"Sreenivasan","year":"2022","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.ejim.2023.10.008_bib0054","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31963","article-title":"Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis","volume":"5","author":"Xiang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2023.10.008_bib0055","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/heartjnl-2014-305538","article-title":"Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction","volume":"100","author":"Kalam","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2023.10.008_bib0056","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.10.008_bib0057","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2015.02.009","article-title":"Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations","volume":"65","author":"Asgar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.10.008_bib0058","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/HJH.0b013e328339f943","article-title":"In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study","volume":"28","author":"Wachtell","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.10.008_bib0059","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.000045","article-title":"Natural history of left ventricular ejection fraction in patients with heart failure","volume":"6","author":"Clarke","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ejim.2023.10.008_bib0060","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jchf.2017.12.014","article-title":"Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF","volume":"6","author":"Savarese","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0061","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.2439","article-title":"Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF","volume":"24","author":"Pab\u00f3n","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0062","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2023.10.008_bib0063","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cccn.2005.05.021","article-title":"Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency department: comparison with brain natriuretic peptide (BNP)","volume":"361","author":"Chenevier-Gobeaux","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejim.2023.10.008_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012336","article-title":"Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"8","author":"Bansal","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2023.10.008_bib0065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0002-9149(79)90235-2","article-title":"Ventricular function and coronary hemodynamics in hypertensive heart disease","volume":"44","author":"Strauer","year":"1979","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2023.10.008_bib0066","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/HJH.0b013e3283516499","article-title":"Impact of lower achieved blood pressure on outcomes in hypertensive patients","volume":"30","author":"Okin","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.10.008_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.123.21454","article-title":"Middle-aged and older patients with left ventricular hypertrophy: higher mortality with drug treated blood pressure below 130\/80mmHg","volume":"80","author":"Heimark","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.10.008_bib0068","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","article-title":"Diabetes, cardiovascular disease and the microcirculation","volume":"17","author":"Strain","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2023.10.008_bib0069","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.10.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001293","article-title":"Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction","volume":"3","author":"van Empel","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"000-000","key":"10.1016\/j.ejim.2023.10.008_bib0071","article-title":"2023 ESH guidelines for the management of arterial hypertension","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T22:38:48Z","timestamp":1715899128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523003643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":71,"alternative-id":["S0953620523003643"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.10.008","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current best drug treatment for hypertensive heart failure with preserved ejection fraction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}